Skip to Content
 
Center for International Blood and Marrow Transplant Research

P-6122

Main Content

Return to Listing

Blood | 2025

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.

Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman CL, Afrough A, Anderson LD Jr., Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau H, Mirza AS, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini MC

PubMed
PMID: 40198886

Abstract
Related Articles

CIBMTR Study #: MM23-01a

Working Committee: Plasma Cell Disorders

Dataset Files:
This dataset was collected by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research; NMDP; and the Medical College of Wisconsin. By downloading the dataset files below, you agree to the Terms and Conditions.
I agree to the Terms and Conditions; Download Dataset

I agree to the Terms and Conditions; Download Data Dictionary